Rapport Therapeutics, Inc. (RAPP) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RAPP currently has 47.2M outstanding shares. with limited dilution risk as only 8.47M additional shares (17.9%) are authorized for issuance. The company has significantly diluted shareholders by 39.95% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 47.2M shares outstanding |
47M | 8.5M |
| Mar 10, 2026 |
10-K filing | 47.8M shares outstanding |
48M | 8.5M |
| Nov 06, 2025 |
10-Q filing | 47.7M shares outstanding |
48M | 8.5M |
| Aug 07, 2025 |
10-Q filing | 35.4M shares outstanding |
35M | 8.5M |
| Jul 01, 2025 |
S-3 filing: The filing is an S-3 form indicating the company's intention to offer common stock, preferred stock and debt securities up to $400,000,000 and also indicates the intention to offer common stock up to $150,000,000 through sales agents. |
35M | 8.5M |
| Jul 01, 2025 |
S-3 filing: This S-3 filing registers 470,589 shares of common stock for resale by a selling stockholder, who received the shares in a private placement, with the company not receiving any proceeds from the sale. |
35M | 8.5M |
| May 08, 2025 |
10-Q filing | 35.3M shares outstanding |
35M | 8M |
| Mar 11, 2025 |
10-K filing | 36.5M shares outstanding |
36M | 8M |
| Nov 07, 2024 |
10-Q filing | 34.9M shares outstanding |
35M | 8M |
| Aug 08, 2024 |
10-Q filing | 36.6M shares outstanding |
37M | 8M |
| Jun 03, 2024 |
S-1/A filing: Initial public offering of shares of common stock of Rapport Therapeutics, Inc. |
35M | 8M |
| May 17, 2024 |
S-1 filing: This S-1 filing relates to the potential issuance of common stock, options, and convertible securities in various scenarios, including dividends, stock splits, QPOs, employee/director compensation, debt/equipment leasing transactions, research collaborations, and acquisitions, with the goal of registering these securities for public offering. |
230M | 30M |